Alberta Investment Management Corp raised its holdings in Neurocrine Biosciences by 10.4% during the 2nd quarter.

Source: https://www.etfdailynews.com/2023/08/25/insider-selling-neurocrine-biosciences-inc-nasdaqnbix-cfo-sells-2132-shares-of-stock/

As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 2.17 EPS for the current year.

Source: https://www.etfdailynews.com/2023/08/25/insider-selling-neurocrine-biosciences-inc-nasdaqnbix-cfo-sells-2132-shares-of-stock/

As a group, sell-side analysts predict that Neurocrine Biosciences will post 2.2 EPS for the current fiscal year.

Source: https://www.etfdailynews.com/2023/09/17/neurocrine-biosciences-nasdaqnbix-earns-overweight-rating-from-cantor-fitzgerald/

Brown Advisory Inc. increased its holdings in Neurocrine Biosciences by 0.5% in the 3rd quarter.

Source: https://www.americanbankingnews.com/2023/02/25/aviva-plc-sells-3537919-shares-of-neurocrine-biosciences-inc-nasdaqnbix.html

Cantor Fitzgerald reaffirmed an “overweight” rating and set a $136.00 price objective on shares of Neurocrine Biosciences in a research note on Tuesday.

Source: https://www.etfdailynews.com/2023/08/25/insider-selling-neurocrine-biosciences-inc-nasdaqnbix-cfo-sells-2132-shares-of-stock/

Congress Asset Management Co. MA raised its holdings in Neurocrine Biosciences by 1.9% in the third quarter.

Source: https://www.etfdailynews.com/2023/02/26/envestnet-asset-management-inc-sells-1903-shares-of-neurocrine-biosciences-inc-nasdaqnbix/

Dupont Capital Management Corp reduced its stake in shares of Neurocrine Biosciences, Inc. () by 15.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).

Source: https://www.etfdailynews.com/2023/04/11/dupont-capital-management-corp-has-284000-stake-in-neurocrine-biosciences-inc-nasdaqnbix/

Finally, raised Neurocrine Biosciences from a buy rating to a strong-buy rating in a report on Thursday, December 7th.

Source: https://www.etfdailynews.com/2023/12/16/deutsche-bank-aktiengesellschaft-initiates-coverage-on-neurocrine-biosciences-nasdaqnbix/

HC Wainwright reaffirmed a “buy” rating and set a $140.00 price objective on shares of Neurocrine Biosciences in a research note on Tuesday.

Source: https://www.etfdailynews.com/2023/02/11/cantor-fitzgerald-weighs-in-on-neurocrine-biosciences-inc-s-fy2023-earnings-nasdaqnbix/

However, the market apparently perceives the deal as a budget-drain for Neurocrine while VYGR stock investors are happily focused on a possible $1.5 billion capital influx for Voyager.

Source: https://investorplace.com/2023/01/voyager-therapeutics-vygr-stock-gains-18-on-gene-therapy-deal/

Morgan Stanley upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $120.00 to $130.00 in a research report on Friday, February 3rd.

Source: https://www.etfdailynews.com/2023/05/23/belpointe-asset-management-llc-makes-new-58000-investment-in-neurocrine-biosciences-inc-nasdaqnbix/

Neurocrine Biosciences had a net margin of 4.19% and a return on equity of 4.06%.

Source: https://www.americanbankingnews.com/2023/01/09/assenagon-asset-management-s-a-sells-54653-shares-of-neurocrine-biosciences-inc-nasdaqnbix.html

The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through William H. Rastetter sold 903 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, April 19th.

Source: https://www.etfdailynews.com/2023/04/26/neurocrine-biosciences-inc-nasdaqnbix-stock-position-raised-by-nisa-investment-advisors-llc/